Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIEPTE study of peripherally targeted DNase inhalation during cystic fibrosis exacerbations
NL-OMON25231Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of dornase alfa in cystic fibrosis (CF) (2 arms), sponsored by Roche. Primary endpoint: Peripheral airway spirometry on study day 12. Started Feb 2006; status: active, not recruiting.
02
Drugs
dornase alfa
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON25231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25231.